Trial Profile
A Phase Ib/II Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Ciprofloxacin (Primary) ; Etoposide (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 05 Jul 2022 Status changed from completed to discontinued.
- 20 Jan 2022 Status changed from active, no longer recruiting to completed.
- 16 Aug 2021 Planned primary completion date changed from 1 Jun 2022 to 1 Sep 2021.